REFERENCES
- Available at http://www.iavi.org. Accessed January 10, 2003.
- Dolin R. Human studies in the development of human immunodeficiency virus vaccines. J Infect Dis. 1995;172(5):1175–1183.
- Burton DR, Montefiori DC. The antibody response in HIV-1 infection. AIDS. 1997;11(suppl A):S87–S98.
- Letvin NL, Barouch DH, Montefiori DC. Prospects for vac-cine protection against HIV-1 infection and AIDS. Annu Rev Immunol. 2002;20:73–99.
- Byrne JA, Oldstone MB. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis vi-rus: clearance of virus in vivo. J ViroL 1984;51:682–686.
- Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency viruses causes AIDS in infant and adult macaques. Nat Med. 1999;5:194–203.
- Fouts TR, Lewis GK, Hone DM. Construction and charac-terization of a Salmonella typi-based human immunodefi-ciency virus type 1 vector vaccine. Vaccine. 1995;6:561–569.
- Stubbs AC, Martin KS, Coeshott C, et al. Whole recombi-nant yeast vaccine activates dentritic cells and elicits pro-tective cell-mediated immunity. Nat Med. 2001;5:625–629.
- Lieberman J, Frankel FR. Engineered Listeria monocytogenes as an AIDS vaccine. Vaccine. 2002;20(15):2007–2010.
- Murphy CG, Lucas WT, Means RE, et al. Vaccine protec-tion against simian immunodeficiency virus by recombi-nant strains of herpes simplex virus. J Virol. 2000;74(17):7745–7754.
- Staats HF, Nichols WG, Palker TJ. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after in-tranasal immunization with the HIV-1 C41V3 peptide T1SP10 MN(A). J Immunol. 1996;157:462–472.
- Kelleher AD, Emery S, Cunningham P, et al. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res Hum Retroviruses. 1997;13:29–32.
- Salmon-Ceron D, Excler JL, Finkielsztejn L, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp 120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses. 1999;15:633–645.
- Srivastava IK, Stamatatos L, Legg H, et al. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J ViroL 2002;76(6):2835–2847.
- Cafaro A, Caputo A, Fracasso C, et al. Control of SHIV-89.6-infection of cynomolgus monkeys by HIV-1 Tat pro-tein vaccine. Nat Med. 1999;6:643–650.
- Huang Y, Chen Z, Zhang W, et al. Adjuvant effects of an NKT ligand, a-galactosylceramide, on DNA vaccination. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract 396.
- Zhang W, Chen Z, Huang Y, Song Y, Ho DD. CTLA4-mediated APC targeting enhanced the humoral and cellular immune responses of an SIV DNA vaccine in mice. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract 397.
- Koup RA. HIV Vaccine research: problems and progress. Top HIV Med. 2002;10(4):9–12.
- Hanson CV. Measuring vaccine-induced HIV neutraliza-tion: report of a workshop. AIDS Res Hum Retroviruses. 1994;10:645–648.
- Currier JR, Kuta EG, Turk E, et al. A panel of MHC class 1 restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002;260:157–172.
- Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year 2000 clinical trial in Kenya. Nat Med. 2000;6:951–955.
- Cao H, Kaleebu P, Hom D, et al. lmmunogenicity of a recombinant human virus (HIV)-canary vaccine in HIV-se-ronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis. 2003;187:887–895.